Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $43.36

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been assigned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $44.1875.

Several analysts recently weighed in on IDYA shares. Citigroup restated a “buy” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. JMP Securities started coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They issued a “market outperform” rating and a $41.00 price target on the stock. Barclays started coverage on shares of IDEAYA Biosciences in a report on Thursday, September 4th. They set an “overweight” rating and a $40.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of IDEAYA Biosciences from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, September 3rd.

Institutional Investors Weigh In On IDEAYA Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC grew its position in IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after acquiring an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. grew its position in IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after acquiring an additional 1,546 shares during the last quarter. Signaturefd LLC boosted its position in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after buying an additional 2,271 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in IDEAYA Biosciences during the 2nd quarter worth approximately $61,000. Finally, Daiwa Securities Group Inc. grew its holdings in IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $29.20 on Friday. The stock has a market capitalization of $2.56 billion, a PE ratio of -7.70 and a beta of 0.14. The business has a fifty day moving average price of $25.93 and a two-hundred day moving average price of $22.40. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $32.67.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The business had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $3.48 million. IDEAYA Biosciences’s quarterly revenue was up NaN% on a year-over-year basis. During the same period in the previous year, the company earned ($0.68) earnings per share. On average, equities analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.